Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of japanese society of chemotherapy, the japanese association for infectious diseases, and the japanese society for clinical microbiology in 2016: General view of the pathogens' antibacterial susceptibility.

The nationwide surveillance on antimicrobial susceptibility of bacterial respiratory pathogens from the patients in Japan was conducted by the Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2016. The isolates were collected from clinical specimens obtained from well-diagnosed adult patients with respiratory tract infections during the period between February 2016 and August 2016 by three societies. Antimicrobial susceptibility testing was conducted at the central reference laboratory according to the method recommended by Clinical Laboratory Standards Institute. Susceptibility testing was evaluated in 1062 strains (143 Staphylococcus aureus, 210 Streptococcus pneumoniae, 17 Streptococcus pyogenes, 248 Haemophilus influenzae, 151 Moraxella catarrhalis, 134 Klebsiella pneumoniae, and 159 Pseudomonas aeruginosa). Ratio of methicillin-resistant S. aureus was 48.3%, and those of penicillin-susceptible S. pneumoniae was 99.5%. Among H. influenzae, 14.1% of them were found to be β-lactamase-producing ampicillin-resistant strains, and 41.1% to be β-lactamase-non-producing ampicillin-resistant strains. Extended spectrum β-lactamase-producing K. pneumoniae and multi-drug resistant P. aeruginosa with metallo β-lactamase were 4.5% and 0.6%, respectively.

Informations de copyright

Copyright © 2020. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of competing interest Katsunori Yanagihara received speaker honoraria from Taisho Toyama Pharmaceutical Co., Ltd., Pfizer Japan Inc., MSD K.K., Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., Nippon Becton Dickinson Company, Ltd., and bioMerieux Japan Ltd., and received scholarship donations from Toyama Chemical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Pfizer Japan Inc., MSD K.K., Taiho Pharmaceutical Co., Ltd., and FUJIFILM Toyama Chemical Co., Ltd. and received research funds from Nippon Becton Dickinson Company, Ltd., Shionogi, Kyorin Pharmaceutical Co., Ltd., Tosoh Corporation, Miyarisan Pharmaceutical Co., Ltd., and FUJIFILM Toyama Chemical Co., Ltd. Tetsuya Matsumoto received speaker honoraria from MSD K·K., and Pfizer Japan Inc. Makoto Miki received speaker honoraria from Kyorin Pharmaceutical Co., Ltd. Yoshitomo Morinaga received research funds from Nippon Becton Dickinson Company, Ltd., Shionogi & Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Tosoh Corporation, Miyarisan Pharmaceutical Co., Ltd., Roche Diagnostics K·K., Beckman Coulter Inc., Parexel International Co., Ltd., and FUJIFILM Toyama Chemical Co., Ltd. Issei Tokimatsu received scholarship donations from Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., and Shionogi & Co., Ltd. Hiroshi Kiyota have received scholarship donations from Taisho Toyama Pharmaceutical Co., Ltd., Toyama Chemical Co., Ltd., Daiichi Sankyo Co., Ltd., Astellas Pharma Inc., Taiho Pharmaceutical Co., Ltd., and Sanofi K·K. Yoshihito Niki received speaker honoraria from Pfizer Japan Inc., MSD K·K., Astellas Pharma Inc., Taisho Toyama Pharmaceutical Co., Ltd., MSD K·K., Sumitomo Dainippon Pharma Co., Ltd., and Asahi Kasei Pharma Corporation, and received scholarship donations from Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., Taiho Pharmaceutical Co., Ltd., MSD K·K., and Shionogi & Co., Ltd. Takahiro Takuma received scholarship donations from Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., and Shionogi & Co., Ltd. Nobuki Aoki received speaker honoraria from Kyorin Pharmaceutical Co., Ltd. Yoshihiro Yamamoto received research fund from Pfizer Japan Inc. Yoshitsugu Iinuma received speaker honoraria from MSD K·K. Atsushi Nakamura received speaker honoraria from MSD K·K., Kyorin Pharmaceutical Co., Ltd., and Astellas Pharma Inc. Hiroshi Kakeya received speaker honoraria from MSD K·K., Pfizer Japan Inc., Sumitomo Dainippon Pharma Co., Ltd., and Astellas Pharma Inc. Koichiro Yoshida received speaker honoraria from MSD K·K. Junichi Kadota received speaker honoraria from MSD K·K., Nippon Boehringer Ingelheim Co., Ltd., and Astrazeneca Co., Ltd., and received research funds from Taisho Toyama Pharmaceutical Co., Ltd., MSD K·K., and Nippon Boehringer Ingelheim Co., Ltd., and received scholarship donation from Daiichi Sankyo Co., Ltd.